Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Green Cross Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Green Cross Corporation - Product Pipeline Review - 2014', provides an overview of the Green Cross Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Green Cross Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Green Cross Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Green Cross Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Green Cross Corporation's pipeline products Reasons to buy - Evaluate Green Cross Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Green Cross Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Green Cross Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Green Cross Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Green Cross Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Green Cross Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Green Cross Corporation Snapshot 6 Green Cross Corporation Overview 6 Key Information 6 Key Facts 6 Green Cross Corporation - Research and Development Overview 7 Key Therapeutic Areas 7 Green Cross Corporation - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Green Cross Corporation - Pipeline Products Glance 14 Green Cross Corporation - Late Stage Pipeline Products 14 Phase III Products/Combination Treatment Modalities 14 Green Cross Corporation - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Phase I Products/Combination Treatment Modalities 16 Green Cross Corporation - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 Green Cross Corporation - Drug Profiles 18 coagulation factor VIII (recombinant) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 GC-1107 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 GC-1112 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 GC-3102C 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 GC-3110A 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 immune globulin (human) 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 MG-1109 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 GC-1102 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 GC-1109 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 idursulfase 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 GC-3106A 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 GCC-2107 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 margetuximab 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 MG-1102 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 MG-4101 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 GC-1118A 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 GC-3111A 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 MG-1111 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Monoclonal Antibody Conjugate to Target Her2 for Breast Cancer 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 rituximab biosimilar 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Green Cross Corporation - Pipeline Analysis 41 Green Cross Corporation - Pipeline Products by Target 41 Green Cross Corporation - Pipeline Products by Route of Administration 43 Green Cross Corporation - Pipeline Products by Molecule Type 44 Green Cross Corporation - Pipeline Products by Mechanism of Action 45 Green Cross Corporation - Recent Pipeline Updates 46 Green Cross Corporation - Dormant Projects 49 Green Cross Corporation - Company Statement 50 Green Cross Corporation - Locations And Subsidiaries 51 Head Office 51 Other Locations & Subsidiaries 51 Appendix 53 Methodology 53 Coverage 53 Secondary Research 53 Primary Research 53 Expert Panel Validation 53 Contact Us 54 Disclaimer 54
List of Tables Green Cross Corporation, Key Information 6 Green Cross Corporation, Key Facts 6 Green Cross Corporation - Pipeline by Indication, 2014 9 Green Cross Corporation - Pipeline by Stage of Development, 2014 10 Green Cross Corporation - Monotherapy Products in Pipeline, 2014 11 Green Cross Corporation - Partnered Products in Pipeline, 2014 12 Green Cross Corporation - Partnered Products/ Combination Treatment Modalities, 2014 13 Green Cross Corporation - Phase III, 2014 14 Green Cross Corporation - Phase II, 2014 15 Green Cross Corporation - Phase I, 2014 16 Green Cross Corporation - Preclinical, 2014 17 Green Cross Corporation - Pipeline by Target, 2014 42 Green Cross Corporation - Pipeline by Route of Administration, 2014 43 Green Cross Corporation - Pipeline by Molecule Type, 2014 44 Green Cross Corporation - Pipeline Products by Mechanism of Action, 2014 45 Green Cross Corporation - Recent Pipeline Updates, 2014 46 Green Cross Corporation - Dormant Developmental Projects,2014 49 Green Cross Corporation, Other Locations 51 Green Cross Corporation, Subsidiaries 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.